Close Menu

NEW YORK – Biopharmaceutical company Precigen said on Monday that the US Food and Drug Administration accepted its investigational new drug application for PRGN-2009, which allows the company to start a Phase I/II trial in patients with HPV-positive solid tumors.

PRGN-2009 is a first-in-class, off-the-shelf investigational immunotherapy that was developed using the company's UltraVector and AdenoVerse platforms to optimize HPV antigen design. The drug works to stimulate the immune system to recognize and target HPV-positive tumors.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Aug
24
Sponsored by
Genecentric

This webinar, Part 1 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss how gene expression signatures can accelerate (and rehabilitate) drug programs, define targeted patient populations, expand drug indications, and improve clinical success.

Sep
10
Sponsored by
Genecentric

This webinar, Part 2 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will focus on the development of RNA-based companion diagnostics for oncology.